Company profile
enGene Holdings Inc.
NASDAQ: ENGN · Healthcare · Biotechnology
Canadian filerHQ Saint-Laurent, CIK 0001980845Reports USD
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH 45DQ —GM —SS 46
v0.1 · 35/100 weight · pillars only
↑ balance-sheet leverage, market scale · ↓ Piotroski F, listing tenure
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$117.3M
Employees
82
as of 2026-08-18
Market cap
$113.9M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$117.3M-$117.3M2025
Operating income-$123.2M-$123.2M2025
Total assets$221.5M$221.5M2025
Liabilities$53.8M$53.8M2025
Equity$167.7M$167.7M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is enGene Holdings Inc.’s financial profile?
enGene Holdings Inc. earned -$117.3M in FY2025 net income.
Peers · Healthcare
Milestone Pharmaceuticals Inc.——Polaryx Therapeutics, Inc. Common Stock——Nautilus Biotechnolgy, Inc.——Biomea Fusion, Inc.——Park Dental Partners, Inc. Common Stock——Hemab Therapeutics Holdings, Inc. Common Stock——Key facts
CEORonald H. W. Cooper
SectorHealthcare
IndustryBiotechnology
HeadquartersSaint-Laurent, null
ExchangeNASDAQ: ENGN
Employees82
IPO date2022-02-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.